|
|
| AUA Guidelines 2020 |
| Advanced Prostate Cancer
|
| William T. Lowrance, MD, MPH and Michael Cookson, MD
|
| The AUA 2020 virtual annual meeting was highlighted by an update on the AUA guidelines for advanced prostate cancer, presented by Dr. William Lowrance and Dr. Michael Cookson. This guideline was produced by a multidisciplinary panel with representation from the AUA, ASCO, ASTRO, and SUO as well as a patient advocate.
|
|
|
|
|
|
| Bladder Cancer (Non-Muscle and Muscle Invasive)
|
Moderator: Sam Chang, MD
Panelists: Elizabeth Plimack, MD, MS, Sima Porten, MD, MPH,
Joshua Meeks, MD, Ph.D., and Ronald Chen, MD, MPH
|
| At the AUA 2020 virtual annual meeting, Sam Chang, MD, MBA, moderated a case-based panel discussion on both non-muscle and muscle-invasive bladder cancer. Areas of focus for this discussion included (i) CIS, (ii) T1 bladder cancer, (iii) multimodality therapy for invasive disease, and (iv) advances for metastatic bladder cancer.
|
|
|
|
|
|
| Benign Prostatic Hyperplasia
|
| Steven Kaplan, MD
|
| Steven Kaplan from the Mount Sinai Medical Center provided updates to the benign prostatic hyperplasia (BPH) guidelines from the surgical side of treatment. The purpose of this guideline is to provide an evidence-based, multidisciplinary useful reference for clinicians that emphasizes shared decision making.
|
|
|
|
|
|
| Microhematuria
|
| Daniel Barocas, MD, MPH, FACS
|
| The guidelines for microhematuria were formulated by a multidisciplinary panel with representations from the American Urological Association, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, and American College of Obstetricians and Gynecologists, as well as Bladder Cancer Advocacy Network patient advocate.
|
|
|
|
|
|
|
|
|
|
|
 |
| Prostate Cancer |
| Androgen Deprivation Therapy: Reducing Morbidity and Improving Outcome
|
| Laurence Klotz, MD, FRCSC
|
| Laurence Klotz gave a presentation elaborating on how to reduce the morbidity and improve the outcomes of androgen deprivation therapy (ADT). The objectives of this talk were to understand the long-term effects of ADT and its association with cardiac disease, metabolic syndrome, bone health, cognitive function, and quality of life.
|
|
|
|
|
|
| Interim Analysis Results of a Prospective Study of 68Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging
|
| Lucia Baratto, MD
|
| In the presented study, the aim was to evaluate Ga-RM2 in prostate cancer patients who experienced biochemical recurrence after primary treatment and had conventional negative imaging. Patients included in the study were those with a biopsy-proven prostatic adenocarcinoma and with a rising PSA after definitive therapy. If patients had surgery, their postoperative PSA had to be greater than 0.2 ng/ml, measured 6 to 13 weeks after radical prostatectomy.
|
|
|
|
|
|
| Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses
|
| Simon Chowdhury, MD
|
| In the phase three TITAN study, it was shown that apalutamide plus ADT significantly improved overall survival, radiographic progression-free survival, and time to prostate-specific antigen progression in a broad population of patients who had metastatic hormone-sensitive prostate cancer. This presentation is a post hoc analysis of the TITAN study that evaluated PSA declines in associations with clinical outcomes.
|
|
|
|
|
|
| Cardiovascular Risk with GnRH Agonists and Antagonists: Real-world Data from UK Primary Care
|
| Patrick Davey, MD
|
| Androgen deprivation therapy in prostate cancer is an effective treatment for a certain period of time and does improve prognosis. However, there is concern over long term side effects, including cardiovascular events. It has been shown that long-term androgen deprivation therapy increases the cardiovascular event rate.
|
|
|
|
|
|
| Bladder Cancer |
| Primary Chemoablation for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial
|
| Seth P. Lerner, MD, FACS
|
| Seth Lerner presented on a study assessing chemoablation in upper tract urothelial carcinoma. Previous data from the compassionate use program have demonstrated that low-grade upper tract urothelial carcinoma can be chemically ablated with UGN-101.
|
|
|
|
|
|
| Can TURBT be Avoided? Primary Chemoablation with a Reverse Thermal Gel Containing Mitomycin (UGN-102) in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
|
| William Huang, MD
|
| William Huang, MD, presented the OPTIMA II study: assessing the efficacy and safety of UGN-102 as primary chemo-ablative therapy in patients with low grade non-muscle invasive bladder cancer at intermediate risk of recurrence. The objective of this study was to evaluate the efficacy and safety of UGN-102 for non-surgical chemo ablation in patients with low-grade intermediate risk non-muscle invasive bladder cancer.
|
|
|
|
|
|
| Phase 3 Results Of Vicinium In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
| Neal Shore, MD, FACS
|
| In a podium presentation at the American Urologic Association Virtual Annual Meeting, Neal Shore and colleagues presented results of a phase 3 trial of Vicinium in patients with BCG-unresponsive NMIBC
|
|
|
|
|
|
| A Phase III Study to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec for Patients with High-Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Papillary Disease Cohort Results |
| Stephen Boorjian, MD |
| At the American Urologic Association Virtual Annual Meeting, Stephen Boorjian and colleagues presented results of the papillary disease cohort of the phase 3 trial of nadofaragene firadenovec. The authors, through the auspices of the SUO CTC, conducted a multicenter, open-label Phase 3 study investigating nadofaragene for high-grade NMIBC (carcinoma in situ [CIS ± Ta/T1], or PD [Ta/T1 alone]) unresponsive to BCG. |
|
|
|
|
|
| Kidney Cancer |
| Surveillance and Communication of Surgical Results in Localized Renal Cell Carcinoma, Results from a Large International Patient Survey
|
| Dena Battle
|
| Dena Battle and colleagues presented results of an international survey of patients with kidney cancer to determine their understanding of their diagnosis, follow-up experience, and assess anxiety that they experience following a diagnosis. The authors utilized data from an international survey generated by KCCure, a non-profit patient advocacy group.
|
|
|
|
|
|
| The IRON Study: Investigation of Robot-Assisted Versus Open Nephron-Sparing Surgery
|
| Alessandro Larcher, MD
|
| Alessandro Larcher and colleagues presented a large, multi-institutional analysis of clinical outcomes after robot-assisted (RAPN) or open partial nephrectomy (OPN). The authors identified 3,468 patients diagnosed with a cT1-2 cN0 cM0 renal mass who underwent RAPN or OPN at 9 high-volume European, North American, or Asian Institutions. These individuals were prospectively identified, and outcomes were collected in a central database.
|
|
|
|
|
|
 |
|
|
|
|
|
